Aura Biosciences (NASDAQ:AURA) Insider Sells $57,461.15 in Stock

Aura Biosciences, Inc. (NASDAQ:AURA) insider Los Pinos Elisabet De sold 9,049 shares of the stock in a transaction dated Wednesday, October 29th. The stock was sold at an average price of $6.35, for a total transaction of $57,461.15. Following the sale, the insider owned 474,391 shares of the company’s stock, valued at $3,012,382.85. This trade represents a 1.87% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Aura Biosciences Stock Performance

Shares of AURA opened at $6.13 on Friday. Aura Biosciences, Inc. has a fifty-two week low of $4.34 and a fifty-two week high of $11.29. The company has a market capitalization of $380.80 million, a price-to-earnings ratio of -3.13 and a beta of 0.45. The firm has a 50-day simple moving average of $6.17 and a 200-day simple moving average of $6.22.

Aura Biosciences (NASDAQ:AURA) last announced its earnings results on Wednesday, August 13th. The company reported ($0.47) earnings per share for the quarter, topping the consensus estimate of ($0.49) by $0.02. Equities research analysts forecast that Aura Biosciences, Inc. will post -1.66 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Tower Research Capital LLC TRC grew its position in Aura Biosciences by 49.3% during the second quarter. Tower Research Capital LLC TRC now owns 6,372 shares of the company’s stock worth $40,000 after buying an additional 2,104 shares during the period. China Universal Asset Management Co. Ltd. grew its position in Aura Biosciences by 24.3% during the second quarter. China Universal Asset Management Co. Ltd. now owns 12,453 shares of the company’s stock worth $78,000 after buying an additional 2,434 shares during the period. American Century Companies Inc. grew its position in Aura Biosciences by 8.3% during the first quarter. American Century Companies Inc. now owns 51,657 shares of the company’s stock worth $303,000 after buying an additional 3,956 shares during the period. Acorn Capital Advisors LLC grew its position in Aura Biosciences by 0.9% during the second quarter. Acorn Capital Advisors LLC now owns 595,744 shares of the company’s stock worth $3,729,000 after buying an additional 5,236 shares during the period. Finally, Harbor Capital Advisors Inc. grew its position in Aura Biosciences by 27.2% during the second quarter. Harbor Capital Advisors Inc. now owns 32,739 shares of the company’s stock worth $205,000 after buying an additional 6,998 shares during the period. 96.75% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Aura Biosciences in a report on Wednesday, October 8th. HC Wainwright reissued a “buy” rating and set a $22.00 price target on shares of Aura Biosciences in a report on Wednesday, August 13th. Finally, Zacks Research raised shares of Aura Biosciences from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 19th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $20.50.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.